Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations.
Willoughby JE, Dou L, Bhattacharya S, Jackson H, Seestaller-Wehr L, Kilian D, Bover L, Voo KS, Cox KL, Murray T, John M, Shi H, Bojczuk P, Jing J, Niederer H, Shepherd AJ, Hook L, Hopley S, Inzhelevskaya T, Penfold CA, Mockridge CI, English V, Brett SJ, Srinivasan R, Hopson C, Smothers J, Hoos A, Paul E, Martin SL, Morley PJ, Yanamandra N, Cragg MS.
Willoughby JE, et al. Among authors: inzhelevskaya t.
J Immunother Cancer. 2024 Jul 4;12(7):e008677. doi: 10.1136/jitc-2023-008677.
J Immunother Cancer. 2024.
PMID: 38964788
Free PMC article.